ÂÜÀòÂÒÂ×

Eamon Brady has over 25 years MedTech experience and is the CEO of WhiteSwell, a science-driven company dedicated to improving treatment of acute decompensated heart failure (ADHF). Prior to WhiteSwell, Eamon was the founder and CEO of Neuravi a stroke interventional company that exited to JNJ in April 2017. Prior to Neuravi Eamon led international teams as both Global Director of R&D and Director of New Ventures at Abbott Vascular. He was a member of the founding team of MedNova Ltd., a company that pioneered embolic protection for carotid stenting, and helped lead the company to an acquisition by Abbott Vascular. Eamon has an engineering background and is a prolific inventor with over 200 US patents, granted or pending. He has a keen interest in all aspects of strategy, building teams and technology, innovation and patient care.